A5038774334- Multiple Myeloma Research and Treatments
- CAR-T cell therapy research
- Protein Degradation and Inhibitors
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Peptidase Inhibition and Analysis
- Immune Cell Function and Interaction
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Hematological disorders and diagnostics
- Cancer Mechanisms and Therapy
- Biosimilars and Bioanalytical Methods
- Viral Infectious Diseases and Gene Expression in Insects
- Fungal Infections and Studies
- Cancer Immunotherapy and Biomarkers
- Antifungal resistance and susceptibility
- Biomedical Research and Pathophysiology
- Immunotherapy and Immune Responses
- Wound Healing and Treatments
- Autophagy in Disease and Therapy
- Chemotherapy-induced organ toxicity mitigation
- Infectious Diseases and Mycology
- Glycosylation and Glycoproteins Research
Ruijin Hospital
2019-2025
Shanghai Institute of Hematology
2019-2025
Shanghai Jiao Tong University
2019-2025
Soochow University
2022
First Affiliated Hospital of Soochow University
2022
Hunan Provincial People's Hospital
2015
Abstract Background LCAR-B38M is a chimeric antigen receptor T cell product with two binding domains targeting B maturation antigen. Our previous reports showed remarkable efficacy of in patients relapsed/refractory multiple myeloma (RRMM) at median follow-up 2 years. Here, we report long-term safety and data from 4 Methods LEGEND-2 was phase 1, single-arm, open-label study conducted four registered sites China. Seventy-four participants RRMM received treatment. Lymphodepletion performed...
Abstract Cytokine release syndrome (CRS) is the most common complication of chimeric antigen receptor redirected T cells (CAR-T) therapy. CAR-T toxicity management has been greatly improved, but CRS remains a prime safety concern. Here we follow serum cytokine levels and circulating immune cell transcriptomes longitudinally in 26 relapsed/refractory multiple myeloma patients receiving product, ciltacabtagene autoleucel, to understand immunological kinetics CRS. We find that although...
Despite the encouraging outcome of chimeric antigen receptor T cell (CAR-T) targeting B maturation (BCMA) in managing relapsed or refractory multiple myeloma (RRMM) patients, therapeutic side effects and dysfunctions CAR-T cells have limited efficacy clinical application this promising approach. In study, we incorporated a short hairpin RNA cassette PD-1 into BCMA-CAR with an OX-40 costimulatory domain. The transduced PD-1KD BCMA were evaluated for surface CAR expression, T-cell...
Oral-drug based regimens are useful in certain circumstances for transplant-ineligible newly diagnosed multiple myeloma (TI-NDMM), but few studies have compared Ixazomib regimen with lenalidomide head-to-head. We carried out a prospective randomized, open, parallel group trial patients TI-NDMM 3 China centers from March 2020 to December 2022. Sixty-three were available final analysis, ICd (Ixazomib/cyclophosphamide/dexamethasone, n = 31) and RCd (lenalidomide/cyclophosphamide/dexamethasone,...
8010 Background: LCAR-B38M CAR-T cells express a structurally differentiated CAR construct containing 4-1BB costimulatory domain and 2 BCMA-targeting single-domain antibodies designed to confer avidity. LEGEND-2 was first-in-human phase 1 study of conducted in China, which showed encouraging efficacy manageable safety 74 patients (pts) with RRMM. The US 1b/2 CARTITUDE-1 Chinese CARTIFAN-1 trials ciltacabtagene autoleucel, expresses the same as LCAR-B38M, confirmed observed LEGEND-2. Here, we...
Although the nephrotoxicity of cisplatin has been well documented as a major side effect chemotherapy, exact mechanism by which prosurvival and apoptotic pathways interplay to determine renal pathology remains elusive. Recent studies suggested that autophagy might serve an adaptive promote cell survival during acute kidney injury (AKI). We have used AKI disease model investigate regulating cytoprotective role in cisplatin-induced tissue damage. Pharmacological inhibitors such chloroquine...
Abstract Background Autologous stem-cell transplantation (ASCT) remains a beneficial approach for patients with newly diagnosed multiple myeloma (NDMM) in the age of novel therapeutic agents. Nevertheless, limited real-world data is available to establish criteria identifying high-risk ASCT patients. Methods We analyzed outcomes 168 NDMM who underwent at our center from December 2015 2022. investigated impact number cytogenetics (HRCA), defined as t(4;14), t(14;16), 1q21 gain/amplification,...
The roles of serum free light chain ratio (sFLCR) in the diagnosis and prognosis newly diagnosed multiple myeloma (NDMM) patients were analyzed.The clinical data was retrospectively analyzed for 82 first affiliated hospital Soochow University from September 28, 2012 to July 18, 2105. levels measured κ/λ ratios calculated, so we could analyze sFLCR patients.It 85.5% (70/82) positive M protein by electrophoresis (SFE) 93.9%(77/82) immunofixation (IFE). Both sFLC abnormalities 96.3% (79/82)....
Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: LCAR-B38M CAR-T cells express a structurally differentiated chimeric antigen receptor (CAR) construct containing 4-1BB costimulatory domain 2 BCMA-targeting single-domain antibodies designed to confer avidity. LEGEND-2 was first-in-human phase 1 study of conducted in China, which showed encouraging efficacy manageable safety 74 patients with relapsed or refractory multiple myeloma (RRMM). The US 1b/2 CARTITUDE-1...
Objective: To assess the safety and effectiveness of amphotericin B cholesteryl sulfate complex for injection in context empirical diagnostic antifungal therapy patients with hematological malignancies addition to invasive fungal illness. Methods: This single-arm clinical study enrolled 30 who received diagnostic-driven combined disease. The primary endpoint was safety. Response rate, fever duration, treatment completion rate were all considered secondary objectives. Results: participants...
Objective: To evaluate the prognostic significance of minimal residual disease (MRD) monitoring by 10-color flow cytometry in multiple myeloma (MM) patients after treatment. Methods: 150 with MM who were admitted to First Affiliated Hospital Soochow University from July 2015 2017 retrospectively analyzed. Clinical data, MRD data and prognosis Results: 39.1% (34/87) negative induction chemotherapy, 49.3% (34/69) within 1 year autologous hematopoietic stem cell transplantation (ASCT) ....
Objective: To summarize the characteristics of patients with newly diagnosed multiple myeloma (NDMM) admitted at Ruijin Hospital affiliated to Shanghai Jiaotong University School Medicine. We compared clinical and prognoses among non-extramedullary disease (EMD), bone-related extramedullary (EM-B) disease, extraosseous (EM-E) further explored effects autologous hematopoietic stem cell transplantation (ASCT) for EMD. Methods: From January 2015 2022, data 114 (22%) EMD out 515 NDMM were...
Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: Extramedullary involvement (or extramedullary disease, EMD) represents an aggressive form of multiple myeloma (MM). Two types EMDs are known to exist: extramedullary‐extraosseous (EM-E) extramedullary‐bone related (EM-B). Although several new EMD treatments available, the prognosis MM patients with remains poor. About 20% newly diagnosed (NDMM) who had at least 1 site impact on outcome in NDMM is influenced by...
Objective: To explore the clinical characteristics and prognosis of multiple myeloma (MM) patients with t(11;14). Methods: The data newly diagnosed MM t(11;14), which confirmed by fluorescence in situ hybridization (FISH), from January 1, 2016 to May 31, 2021 Ruijin Hospital Affiliated Shanghai Jiao Tong University School Medicine was retrospectively collected. A total 45 were included. Bortezomib based induction therapy given 88.9% (40/45) patients, while 11.1% (5/45) received Imids-based...
Objective: To explorer Secretory mature B cell surface antigen (sBCMA) expression level, changes during treatment and clinical significance in newly diagnosed MM patients. Methods: Clinical data of 158 patients admitted to the Department Hematology, First Affiliated Hospital Soochow University from August 2018 September 2020 were analyzed retrospectively. The concentration sBCMA was determined by BCMA ELISA compared with normal range. results efficacy, age, type, R-ISS stage, renal...